Prevalence and associated malignancy of Bethesda category III cytologies of thyroid nodules assigned to the “cytological atypia” or “architectural atypia” groups

Cibas, 2009, The 2017 Bethesda system for reporting thyroid cytopathology, Am J Clin Pathol, 132, 658, 10.1309/AJCPPHLWMI3JV4LA Nishino, 2014, Should the thyroid AUS/FLUS category be further stratified by malignancy risk?, Cancer Cytopathol, 122, 481, 10.1002/cncy.21412 Cibas, 2017, The Bethesda system for reporting thyroid cytopathology, Thyroid, 27, 1341, 10.1089/thy.2017.0500 Heller, 2014, Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS): is there a correct answer?, Thyroid, 24, 787, 10.1089/thy.2014.0142 Ho, 2014, Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS), Thyroid, 24, 832, 10.1089/thy.2013.0317 López, 2015, Riesgo de malignidad de los nódulos tiroideos con atipia de significado incierto, Endocrinol Nutr, 62, 507, 10.1016/j.endonu.2015.06.007 Tamhane, 2016, Thyroid nodule update on diagnosis and management, Clin Diabetes Endocrinol, 2, 17, 10.1186/s40842-016-0035-7 Padmanabhan, 2017, Diagn Cytopathol, 45, 399, 10.1002/dc.23681 Ferris, 2015, American Thyroid Association Surgical Affairs Committe American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making, Thyroid, 25, 760, 10.1089/thy.2014.0502 Haugen, 2016, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 26, 1, 10.1089/thy.2015.0020 Na, 2015, Role of core needle biopsy in the management of atypia/follicular lesion of undetermined significance thyroid nodules: comparison with repeat fine-needle aspiration in subcategory nodules, Eur Thyroid J, 4, 189, 10.1159/000437051 De Koster, 2018, Diagnostic utility of molecular and imaging biomarkers in cytological indeterminate thyroid nodules, Endocr Rev, 39, 154, 10.1210/er.2017-00133 Brito, 2014, The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and metaanalysis, J Clin Endocrinol Metab, 99, 1253, 10.1210/jc.2013-2928 Remonti, 2015, Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies, Thyroid, 25, 538, 10.1089/thy.2014.0353 Renshaw, 2010, Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified?, Cancer Cytopathol, 118, 186, 10.1002/cncy.20091 Renshaw, 2011, Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid, Cancer Cytopathol, 119, 322, 10.1002/cncy.20154 Shrestha, 2016, Cytologic subclassification of atypia of undetermined significance may predict thyroid nodules more likely to be malignant at surgery, Diag Cytopathol, 44, 492, 10.1002/dc.23472 Chandra, 2017, Malignancy rate in thyroid nodules categorized as atypia of undeterminated significance of follicular lesion of undetermined significance. An institucional experience, J Cytol, 34, 144, 10.4103/JOC.JOC_234_16 Gan, 2017, Thyroid cytology-nuclear versus architectural atypia within the “Atypia of undetermined significance/follicular lesion of undetermined significance”. Bethesda category have significantly different rates of malignancy, Cancer Cytopathol, 125, 245, 10.1002/cncy.21823 Rosario, 2017, Importance of cytological subclassification of thyroid nodules with Bethesda category III cytology (AUS/FLUS) into architectural atypia only and nuclear atypia: a prospective study, Diag Cytopathol, 45, 604, 10.1002/dc.23734 Valderrabano, 2018, Cancer risk associated with nuclear atypia in cytologically indeterminate thyroid nodules: a systematic review and meta-analysis, Thyroid, 28, 210, 10.1089/thy.2017.0419 VanderLaan, 2011, Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance, Am J Clin Pathol, 136, 572, 10.1309/AJCPO0BQ2YSKPXXP Tuttle, 2017, Thyroid differentiated and anaplastic carcinoma Lee, 2016, Subcategorization of Bethesda system category III by ultrasonography, Thyroid, 26, 836, 10.1089/thy.2015.0637 Straccia, 2015, Meta-analytic review of the Bethesda system for reporting thyroid cytopathology: has the rate of malignancy in indeterminate lesions been underestimated?, Cancer Cytopathol, 123, 713, 10.1002/cncy.21605 Horne, 2012, Thyroid follicular lesion of undetermined significance: evaluation of the risk of malignancy using the two-tier sub-classification, Diagnostic Cytopathol, 40, 410, 10.1002/dc.21790 Rosario, 2014, Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory, Thyroid, 24, 1115, 10.1089/thy.2013.0650 Hyeon, 2014, The prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results, Cancer Cytopathol, 122, 368, 10.1002/cncy.21396 Kim, 2017, Risk of malignancy according to subclassification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology, Cytopathology, 28, 65, 10.1111/cyt.12352 Ahn, 2017, Comparison of risk of malignancy ina subgroup with atypia of undetermined significance/follicular lesion of undetermined significance: a meta-analysis, Head Neck, 39, 1699, 10.1002/hed.24768 Walts, 2014, Follicular lesion of undetermined significance in thyroid FNA revisited, Diagnostic Cytopathol, 42, 18, 10.1002/dc.23019